A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that causes breathing difficulties by blocking ...
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable condition marked by breathlessness, chronic ...
Chronic respiratory failure is associated with earlier and greater risks of cardiovascular diseases among individuals with COPD.
Novel drug effective for asthma, COPD Reviewers are questioning the safety profile of combination umeclidinium/vilanterol after noting inconsistencies in data from ...
Today is World COPD Day, and the American Lung Association is spotlighting a free program to provide personalized, one-on-one support to people living with COPD. The Lung Health Navigator program is ...
Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults with post- and precapillary pulmonary hypertension due to heart failure. The Rahway, N.J., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback